The executive order signed by US President Donald Trump to accelerate research, evaluation, and responsible access to innovative treatments for severe mental health conditions, including psychedelic-assisted therapies, places the field of mental healthcare at a critical crossroads.
On one hand, it offers genuine hope for millions of patients struggling with treatment-resistant depression, post-traumatic stress disorder (PTSD), addiction, and other complex psychiatric conditions.
On the other hand, it raises legitimate concerns about the risks of accelerating highly sensitive medical, scientific, and regulatory processes too quickly.
Yet it is precisely within this tension that a clear conclusion emerges: this move is not only legitimate- it is necessary, provided it is done responsibly.
The current reality is unsustainable. Mental health systems worldwide are facing growing pressure, while many existing treatment options fail to provide adequate relief for a significant portion of patients.
(Illustrative) A customs officer displays Captagon pills. Sofia, 12, 2007. (credit: REUTERS/Nikolay Doychinov )
Treatment-resistant depression, PTSD, and severe addiction are not abstract concepts; they are daily realities affecting individuals, families, and entire healthcare systems.
Within this gap, psychedelic compounds and related molecules, including ibogaine, offer a new scientific avenue worth serious exploration. Not as a shortcut, and certainly not as a miracle cure, but as a promising field that deserves rigorous scientific evaluation through the standards of modern medicine.
This point must be stated clearly: regulatory acceleration should never mean lowering safety standards. Quite the opposite. Responsible acceleration means allocating more resources, improving coordination between regulatory agencies, creating greater regulatory clarity, and reaching scientific answers faster, not bypassing them.
Even according to the administration’s stated approach, the goal is not to “circumvent science,” but to remove bureaucratic barriers that delay research and responsible access to potentially transformative therapies. In other words, this is not about cutting corners; it is about correcting systemic stagnation.
Of course, there are risks. The psychiatric and scientific communities are right to warn about possible psychological and physiological side effects, unregulated use, and public enthusiasm that may outpace clinical evidence. But risk alone cannot justify paralysis. It demands responsible management.
Mental health research has been neglected
And that is precisely where the value of this order lies.
For years, the field of mental health has suffered from regulatory neglect and public stigma, leaving major areas of research underdeveloped and patients with too few effective options.
The current acceleration does not eliminate the need for safety; rather, it enables the medical community to generate knowledge more efficiently, under controlled conditions, while building advanced therapeutic and clinical infrastructures.
The use of these substances must occur under strict medical supervision, within structured clinical trials, supported by clear protocols, robust safety monitoring, appropriate patient selection, and comprehensive professional oversight. But to reach that stage, research must first be allowed to move forward.
Moreover, there is a broader strategic opportunity at play. The United States is signaling its willingness to lead the next generation of mental health treatments and revive a field where innovation has stagnated for decades.
Such a move could have implications far beyond US borders: accelerating scientific and clinical development, establishing new global standards, and encouraging other countries to reconsider how they address the ongoing mental health crisis.
Criticism of the “speed” of this initiative is understandable. But it often overlooks the fact that the status quo is also dangerous.
When effective treatments are unavailable, patients frequently turn to unregulated markets, illegal therapies, and, at times, far more destructive alternatives. Responsible regulatory acceleration may actually reduce those risks by bringing these treatments into the medical system rather than leaving them outside it.
It is important to emphasize that ibogaine and other psychedelic compounds are not “miracle drugs.” They are potentially powerful and highly complex medical tools that require rigorous research, controlled manufacturing, deep scientific understanding, and comprehensive regulatory oversight.
For that very reason, the correct path is not to isolate this field from mainstream medicine, but to integrate it into it, under the frameworks of science, regulation, and accountability.
This is also why biotechnology companies operating in this space, including PsyRx, must adopt a responsible and cautious approach: transforming scientific potential into safe, precise, and accessible medical treatments without making premature promises or compromising the strict standards of pharmaceutical development.
Ultimately, the question is not whether research should be accelerated, but whether we can afford to continue delaying it.
Trump’s order is not perfect. It requires oversight, transparency, responsibility, and caution. But it does one thing right: it moves the system forward.
And in a world facing a prolonged mental health crisis, that is not a luxury; it is an obligation.
Because sometimes, the real risk is not innovation. It is standing still.
The writer is a physician specializing in public health and epidemiology, former deputy director-general of Israel’s Health Ministry and former head of Public Health Services. He served on the Executive Board of the World Health Organization and led major strategic initiatives within Israel’s healthcare system. He is a full professor at Ben-Gurion University of the Negev and author of more than 220 scientific publications. He currently serves as chairman of PsyRx, which is developing an ibogaine-based treatment for severe depression.